Chronic lymphocytic leukemia natural history, complications and prognosis: Difference between revisions
Line 46: | Line 46: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Performance status'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Performance status'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:* Patient's poor performance status is associated with a worse prognosis. | :* Patient's poor [[performance status]] is associated with a worse prognosis. | ||
|- | |- | ||
Line 55: | Line 55: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte doubling time'''|| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte doubling time'''|| style="padding: 5px 5px; background: #F5F5F5;" | | ||
:*A rapid lymphocyte doubling time is associated with a worse prognosis | :*A rapid [[lymphocyte]] doubling time is associated with a worse prognosis | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetic mutations'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetic mutations'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:*Deletion of chromosome 17 short arm | :*Deletion of [[chromosome 17]] short arm and [[chromosome 11]] long arm are associated with a worse prognosis. | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Prolymphocytes percent'''|| style="padding: 5px 5px; background: #F5F5F5;" | | |style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Prolymphocytes percent'''|| style="padding: 5px 5px; background: #F5F5F5;" | | ||
:*An increased percentage of | :*An increased percentage of [[prolymphocyte]]s is associated with a worse prongnosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Histological analysis'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Histological analysis'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:*Diffuse histology on bone marrow aspiration is associated with a worse prognosis. | :*Diffuse [[histology]] on [[bone marrow aspiration]] is associated with a worse prognosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lactate dehydrogenase (LDH) level'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lactate dehydrogenase (LDH) level'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:*Elevated levels of LDH are associated with a worse prognosis. | :*Elevated levels of [[LDH]] are associated with a worse prognosis. | ||
|- | |- | ||
Line 85: | Line 85: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface marker'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface marker'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:* | :*Over expression of [[CD38]] is associated with a worse prognosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Immunoglobulin (Ig)VH gene'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Immunoglobulin (Ig)VH gene'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:*The absence of | :*The absence of IgVH [[gene]] mutation is associated with a worse prognosis. | ||
|- | |- |
Revision as of 19:56, 14 October 2015
Chronic lymphocytic leukemia Microchapters |
Differentiating Chronic lymphocytic leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Chronic lymphocytic leukemia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Chronic lymphocytic leukemia natural history, complications and prognosis |
FDA on Chronic lymphocytic leukemia natural history, complications and prognosis |
CDC on Chronic lymphocytic leukemia natural history, complications and prognosis |
Chronic lymphocytic leukemia natural history, complications and prognosis in the news |
Blogs on Chronic lymphocytic leukemia natural history, complications and prognosis |
Directions to Hospitals Treating Chronic lymphocytic leukemia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
Most patients with chronic lymphocytic leukemia are initially asymptomatic. If left untreated, patients with chronic lymphocytic leukemia may progress to develop weight loss, fever, and lymph node swelling. Common complications of chronic lymphocytic leukemia include immunodeficiency, warm autoimmune hemolytic anemia, and Richter's transformation.[1] Prognosis is generally good, and the 5-year survival rate of patients with chronic lymphocytic leukemia is approximately 81.7%.[2]
Natural History, Complications and Prognosis
Natural History
- Most patients with chronic lymphocytic leukemia are initially asymptomatic.
- If left untreated, patients with chronic lymphocytic leukemia may progress to develop weight loss, fever, and lymph node swelling.[1]
Complications
Prognosis
- Prognosis is generally good, and the 5-year survival rate of patients with chronic lymphocytic leukemia is approximately 81.7%.[2]
- Common prognostic factors for meningioma chronic lymphocytic leukemia patients age, tumor stage, and the presence of certain genetic mutations.
- The table below lists prognostic factors for chronic lymphocytic leukemia:[3][4]
Prognostic Factor | Description |
---|---|
Age |
|
Gender |
|
Performance status |
|
Stage |
|
Lymphocyte doubling time |
|
Genetic mutations |
|
Prolymphocytes percent |
|
Histological analysis |
|
Lactate dehydrogenase (LDH) level |
|
β2-microglobulin level |
|
Lymphocyte surface marker |
|
Immunoglobulin (Ig)VH gene |
|
Membrane-bound proteins |
|
References
- ↑ 1.0 1.1 1.2 Chronic Lymphocytic Leukimea. Wikipedia (2015) https://en.wikipedia.org/wiki/B-cell_chronic_lymphocytic_leukemia Accessed on October ,12 2015
- ↑ 2.0 2.1 SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. National Cancer Institute (2015) http://seer.cancer.gov/statfacts/html/clyl.html Accessed on October, 12 2015
- ↑ 3.0 3.1 Nabhan C, Rosen ST (2014). "Chronic lymphocytic leukemia: a clinical review". JAMA. 312 (21): 2265–76. doi:10.1001/jama.2014.14553. PMID 25461996.
- ↑ Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011